The UK has launched a new initiative to accelerate the testing of potential new therapies for COVID-19, under which the time taken to set up clinical trials would be reduced “from months to just weeks,” according to the Department of Health and Social Care (DHSC).
UK To Speed New COVID-19 Drug Candidates Into Trials
Collaborative Project Hailed As ‘Transformative’
The first of six new compounds are expected to begin Phase II testing soon as part of the UK’s ACCORD initiative, a randomized platform trial bringing together government, industry and research organisations to find potential treatments for COVID-19.
More from United Kingdom
Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry
• By
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
• By
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
• By
The policy expectation that the model clinical trial agreements are used without modification is in line requests from industry and the NHS/HSC.
• By
Efforts by the medicines regulator, the MHRA, to clear all backlogs relating to its statutory functions and maintaining predictable review timeframes have put pressure on its staff.